drugset / Trial / NCT01959035

Aripiprazole Once-monthly in Patients With Schizophrenia

NCT01959035

NaSingle-groupOpen-labelTreatment

Summary

To obtain information on the safety, tolerability and effectiveness of aripiprazole once-monthly in a manner consistent with its intended use in everyday clinical practice in patients with schizophrenia who completed Study 14724A / NCT01795547.

Timeline

Start
2013-10
Primary completion
2015-03
Completion
2015-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Aripiprazole Other / unclassified 300 mg Intramuscular
Subject Aripiprazole Other / unclassified 400 mg Intramuscular

Indications